List of Excipients in Branded Drug ROCALTROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	ROCALTROL	calcitriol	30698-143	BUTYLATED HYDROXYANISOLE
Validus Pharmaceuticals LLC	ROCALTROL	calcitriol	30698-143	BUTYLATED HYDROXYTOLUENE
Validus Pharmaceuticals LLC	ROCALTROL	calcitriol	30698-143	COCONUT OIL
Validus Pharmaceuticals LLC	ROCALTROL	calcitriol	30698-143	FD&C YELLOW NO. 6
Validus Pharmaceuticals LLC	ROCALTROL	calcitriol	30698-143	GLYCERIN

ROCALTROL Excipient Strategy and Commercial Opportunities for Calcitriol Capsules

Last updated: July 31, 2026

Rocaltrol is the Roche brand for calcitriol, the active vitamin D metabolite used primarily in hypocalcemia associated with renal osteodystrophy, hypoparathyroidism, and related disorders. Its core formulation uses a lipid vehicle, with calcitriol dissolved in fractionated coconut oil and enclosed in a soft gelatin capsule. The principal commercial opportunity is therefore not broad patent exclusivity. It is differentiated generic development based on dose accuracy, low-dose content uniformity, capsule performance, storage stability, and alternative dosage forms.

Rocaltrol's original composition is relatively simple, but calcitriol is highly potent. The product contains 0.25 mcg or 0.5 mcg per capsule, making manufacturing controls and analytical sensitivity more important than the number of excipients. Generic manufacturers can compete through supply reliability, contract manufacturing, packaging, hospital contracting, and formulations that address swallowing, dietary restrictions, or pharmacy handling.

What is Rocaltrol and which calcitriol products compete with it?

Rocaltrol contains calcitriol, chemically 1alpha,25-dihydroxyvitamin D3. Unlike nutritional vitamin D products, calcitriol is the active hormonal metabolite and does not require renal activation. The drug is marketed in very low strengths, where small absolute assay errors can materially affect dose delivery.

Product characteristic	Rocaltrol
Active ingredient	Calcitriol
Brand owner/originator	Roche
Dosage forms	Soft gelatin capsules; oral solution has also been associated with the Rocaltrol product family in certain markets
Capsule strengths	0.25 mcg and 0.5 mcg
Primary clinical use	Hypocalcemia and disorders of calcium and phosphate metabolism
US approval history	Long-standing FDA-approved product; original approval predates modern Hatch-Waxman exclusivity practices
Competitive status	Generic calcitriol capsules are available
Principal formulation issue	Accurate delivery of a microgram-level dose in a lipid-filled softgel

The main competing therapies are not direct formulation substitutes in every indication. They include paricalcitol, doxercalciferol, alfacalcidol in markets where approved, and nonactive vitamin D products such as cholecalciferol and ergocalciferol. Cinacalcet and etelcalcetide compete in selected secondary hyperparathyroidism treatment pathways but have different mechanisms and dosing profiles.

What excipients are used in Rocaltrol capsules?

Rocaltrol capsules use fractionated coconut oil as the principal internal vehicle. The capsule shell contains conventional softgel components, including gelatin and plasticizers. Public labeling identifies excipients that include glycerin, sorbitol, titanium dioxide, and colorants depending on strength and market presentation. Product-specific labeling should control for the target jurisdiction because excipient declarations can vary by country and manufacturing site.[1]

Formulation component	Strategic function	Commercial relevance
Calcitriol	Active pharmaceutical ingredient	Requires microgram-level assay and content-uniformity control
Fractionated coconut oil	Lipid vehicle and solubilizing medium	Supports dissolution of the highly potent, lipophilic active
Gelatin	Softgel shell former	Creates animal-origin and dietary-status considerations
Glycerin	Plasticizer and shell-moisture modifier	Affects shell flexibility and stability
Sorbitol	Plasticizer or shell-processing aid	Can affect shell behavior and excipient tolerability
Titanium dioxide and colorants	Opacity, identification, and presentation	May require reformulation for market-specific restrictions
Packaging system	Protection from light, heat, and oxygen	Important because calcitriol is sensitive to degradation

The formulation's commercial value lies in reproducibility. A manufacturer must distribute a very small quantity of calcitriol uniformly through the fill material and maintain that distribution during encapsulation, storage, and shipment.

How does the excipient strategy affect calcitriol stability?

Calcitriol is sensitive to light, oxygen, heat, and formulation conditions. The lipid vehicle can improve dissolution and support uniform dosing, but it also requires control of oxidation and fill homogeneity. The finished product should be evaluated for assay, related substances, dissolution, capsule integrity, fill-weight variation, and degradation under accelerated and long-term conditions.

A generic developer should evaluate:

1. Solubility and dispersion of calcitriol in the selected lipid vehicle.
2. Mixing time and temperature during bulk preparation.
3. Protection from light during compounding and encapsulation.
4. Oxygen exposure, including headspace and packaging effects.
5. Interaction between the fill and gelatin shell.
6. Water migration between the fill and shell.
7. Content uniformity across the commercial batch.
8. Stability after opening a bottle or blister package.

The key formulation risk is dose uniformity rather than conventional tablet disintegration. At 0.25 mcg, a minor blend or fill-distribution problem can produce a clinically meaningful relative dose deviation.

What formulations are protected by Rocaltrol patents?

Rocaltrol's original composition is not protected by a commercially meaningful US patent estate today. The principal opportunities are generic or line-extension products rather than a new chemical-entity patent strategy.

Historic calcitriol patents covered the compound and early therapeutic uses. Those rights expired long ago. Current competitive protection is more likely to arise from manufacturing know-how, formulation development, analytical methods, trademarks, regulatory data, and supply arrangements than from enforceable composition-of-matter patents.

Potentially protectable developments include:

• A stabilized lipid vehicle with improved impurity control.
• A non-gelatin capsule shell.
• A low-oxygen manufacturing process.
• A liquid formulation with improved dose uniformity.
• A unit-dose ampule or oral syringe presentation.
• A pediatric formulation with controlled low-volume dosing.
• A formulation that excludes specific allergens or animal-derived ingredients.
• A manufacturing process that reduces calcitriol loss during encapsulation.

These developments would require a separate patentability analysis. A formulation patent would need a defensible combination of composition, performance, and unexpected stability or bioavailability results. Routine substitution of one pharmaceutical lipid or plasticizer for another would face a higher obviousness risk.

When does Rocaltrol lose exclusivity?

Rocaltrol has already lost practical market exclusivity in the United States. Generic calcitriol capsules have been marketed for years, and the product is not dependent on a current blockbuster patent expiry date.

Exclusivity category	Rocaltrol position
Composition-of-matter patent	Expired
Original FDA regulatory exclusivity	Expired
Current US patent barrier	No commercially significant barrier identified in standard public product records
Generic pathway	ANDA-based competition for equivalent capsule strengths
Brand protection	Trademark and commercial recognition, not molecule exclusivity
Biosimilar exposure	None; calcitriol is a small molecule, not a biologic

The relevant regulatory question for a new entrant is whether the proposed product can meet the requirements for an ANDA referencing the listed drug, including pharmaceutical equivalence, bioequivalence where required, manufacturing controls, and labeling conformity.[2]

What is the Orange Book status of Rocaltrol?

The FDA Orange Book is the primary source for listed-drug, patent, and exclusivity information relevant to abbreviated applications. Rocaltrol's current commercial position is consistent with an off-patent reference product. Historical listing information should be checked against the current electronic Orange Book and FDA Drugs@FDA records before filing or acquisition decisions.[2,3]

For a generic calcitriol capsule, the regulatory work typically includes:

• Reference to the appropriate Rocaltrol listed drug.
• Demonstration of pharmaceutical equivalence.
• Comparative dissolution and product-performance data.
• Stability data supporting the proposed shelf life.
• Validation of low-dose assay and content-uniformity methods.
• Assessment of inactive-ingredient differences.
• Labeling that matches the reference product unless a permitted difference applies.

An excipient change does not automatically create a new regulatory pathway. It can, however, create additional safety, equivalence, stability, or labeling issues.

What commercial opportunities exist for Rocaltrol excipient innovation?

The strongest opportunities are in narrow, defensible segments rather than mass-market substitution.

Low-dose generic capsules

A manufacturer with reliable microdose softgel capabilities can compete on quality and supply continuity. The product is suitable for an established generic portfolio, particularly where the manufacturer already produces lipid-filled capsules.

Vegetarian or non-animal capsules

A non-gelatin shell could address religious, dietary, or institutional procurement requirements. The development burden includes shell compatibility, oxygen and moisture transmission, sealing performance, dissolution, and long-term stability. A plant-based shell is commercially relevant only if it preserves product performance and does not materially increase cost.

Oral liquid or unit-dose presentations

An oral liquid could target patients who cannot swallow capsules, pediatric use, nursing facilities, and dose titration. The main risks are chemical stability, adsorption to dosing devices, microbial control, preservative selection, and accurate delivery at very small volumes.

A unit-dose presentation could reduce pharmacy manipulation and improve dose traceability. It may also support institutional channels where packaging and medication-error control influence purchasing.

Specialty and regional markets

Some markets use calcitriol in dialysis, nephrology, endocrine, and hospital settings. A supplier can differentiate through local registration, reliable cold-chain or controlled-temperature logistics where needed, and packaging adapted to institutional dispensing.

Excipient-restricted formulations

Products excluding gelatin, selected colorants, or specific allergen-related materials may win targeted contracts. The commercial case depends on actual procurement requirements because many patients do not require an alternative excipient system.

How strong is the patent estate for a new calcitriol formulation?

The patent estate is weak for the legacy product and potentially moderate for a genuinely differentiated formulation. Strength depends on claim scope, technical effect, freedom to operate, and the ability to demonstrate non-obvious performance.

Development concept	Likely IP position	Main barrier
Same calcitriol strength in same softgel format	Weak	Crowded generic field and expired core rights
Alternative lipid vehicle	Moderate if performance is unexpected	Obviousness and design-around risk
Non-gelatin shell	Moderate	Shell compatibility and prior-art overlap
Stable oral liquid	Moderate to strong if stability is distinctive	Formulation and device prior art
Pediatric unit-dose system	Moderate	Combination of formulation and packaging claims
New clinical use	Potentially stronger	Must establish a patentable, legally supportable method of use
Manufacturing process	Moderate	Detectability and enforcement of process claims

Process patents are difficult to enforce when manufacturing occurs outside the jurisdiction or when the process cannot be detected from the finished product. Composition and product-by-process claims generally provide stronger commercial leverage when the product has a measurable distinguishing property.

Which companies are challenging Rocaltrol?

Generic competition comes from manufacturers that have obtained or marketed calcitriol products through abbreviated applications or national generic pathways. The competitive field can change because products enter, exit, or become unavailable without a change in the underlying patent position.

The relevant competitive set includes:

• Generic manufacturers of calcitriol softgel capsules.
• Specialty pharmaceutical companies supplying nephrology products.
• Contract manufacturers with softgel and lipid-fill capabilities.
• Developers of alternative vitamin D receptor activators.
• Regional manufacturers offering calcitriol oral solutions or hospital presentations.

Public regulatory databases are more reliable than distributor catalogs for determining current approval and marketing status. A product may remain approved while being commercially unavailable, or may appear in procurement data without broad retail distribution.

What generic entry risks exist for a new Rocaltrol competitor?

The principal risks are operational and regulatory.

Manufacturing risk

Calcitriol is potent at microgram quantities. Losses on equipment surfaces, incomplete mixing, fill-weight variation, and sampling bias can disrupt content-uniformity results. Dedicated cleaning validation and highly sensitive analytical methods are central to batch release.

Stability risk

The developer must control light, oxygen, heat, and moisture. Packaging selection can determine whether the product meets its labeled shelf life. Bottles, blisters, and unit-dose systems should be compared using real-time and accelerated data.

Regulatory risk

A changed excipient system can trigger questions about safety, equivalence, dissolution, or labeling. The ANDA strategy should minimize unnecessary formulation differences unless the difference has a clear commercial purpose.

Commercial risk

The market is mature and price-sensitive. A new entrant needs either a cost advantage, a supply advantage, a differentiated dosage form, or access to a specialty channel. A conventional duplicate capsule with no manufacturing advantage is likely to face rapid price erosion.

Does calcitriol have biosimilar risk?

No. Calcitriol is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic drugs, authorized generics, alternative vitamin D analogs, and other therapies for mineral-bone disorders. FDA biosimilar approval standards do not apply to calcitriol capsules.[4]

How does Rocaltrol compare with paricalcitol and doxercalciferol?

Rocaltrol, paricalcitol, and doxercalciferol all operate in the vitamin D and mineral-metabolism market, but their formulation and regulatory profiles differ.

Factor	Calcitriol/Rocaltrol	Paricalcitol	Doxercalciferol
Molecular category	Active vitamin D metabolite	Vitamin D analog	Prodrug activated in the liver
Main competitive area	Hypocalcemia and renal mineral-bone disorders	Secondary hyperparathyroidism	Secondary hyperparathyroidism
Typical commercial format	Low-dose capsules and other regional forms	Capsules and injectable products	Capsules
Generic status	Mature generic competition	Generic competition exists	Generic competition exists
Excipient opportunity	Microdose softgel, oral liquid, shell alternatives	Formulation and injectable opportunities	Capsule and dose-flexibility opportunities
Biosimilar pathway	Not applicable	Not applicable	Not applicable

The commercial advantage of calcitriol is familiarity and established use. Its disadvantage is limited differentiation in a mature generic market and a narrow therapeutic margin requiring careful calcium and phosphate monitoring.

What patent litigation and Paragraph IV challenges affect Rocaltrol?

Rocaltrol is not presently defined by an active US patent-litigation cycle comparable to recently launched branded drugs. Because the core product rights are historic and generic competition is established, a new entrant is more likely to face ordinary abbreviated-application review, manufacturing scrutiny, pricing pressure, and contracting competition than a Paragraph IV injunction campaign.

A Paragraph IV certification would become relevant only if the proposed ANDA referenced a listed drug with a qualifying unexpired patent. Developers should verify current Orange Book listings before filing because patent listings and regulatory records can change.[2]

What licensing deals could create value around calcitriol?

Licensing value is most credible in three areas:

1. A differentiated dosage form, especially a stable oral liquid or unit-dose product.
2. Access to a validated softgel manufacturing platform in a region where calcitriol supply is limited.
3. A specialty commercial partnership covering nephrology, dialysis, endocrine, or institutional channels.

A license covering only the basic calcitriol molecule is unlikely to provide meaningful exclusivity. A stronger deal would combine formulation IP, manufacturing know-how, regulatory approvals, and guaranteed supply capacity.

What is the revenue exposure and market outlook for Rocaltrol?

The branded product has limited strategic value compared with its historical position because generic calcitriol is available and the active ingredient is off-patent. Revenue exposure is concentrated in:

• Brand retention among physicians and pharmacies.
• Institutional and specialty distribution.
• Geographic markets with fewer generic competitors.
• Shortages or discontinuations affecting generic supply.
• Premium dosage forms that solve administration or adherence problems.

A conventional generic capsule should be modeled as a low-margin, volume-driven product. An alternative formulation can support a higher price only if it offers measurable benefits, such as easier administration, improved stability, reduced excipient restrictions, or reliable unit-dose delivery.

Key Takeaways

• Rocaltrol contains calcitriol in a lipid-filled softgel formulation.
• Fractionated coconut oil is the central formulation excipient and supports dissolution of the potent, lipophilic active.
• The original calcitriol patent estate and regulatory exclusivity have expired.
• Generic competition, not patent litigation, defines the US market.
• The main technical challenge is microgram-level dose uniformity and stability.
• Commercial opportunities include non-gelatin capsules, oral liquids, unit-dose packaging, and specialty-channel supply.
• A new formulation patent needs measurable technical advantages, not routine excipient substitution.
• Calcitriol has generic risk, not biosimilar risk.
• Licensing value is strongest when formulation IP is combined with manufacturing capability and commercial access.

FAQs

Can a company use the same fractionated coconut oil formulation as Rocaltrol?

Yes, subject to regulatory requirements, intellectual-property review, manufacturing validation, and product-performance testing. The excipient itself is not a current source of meaningful exclusivity.

Is a calcitriol oral liquid commercially attractive?

It can be attractive for pediatric, dysphagia, nursing-home, and dose-titration markets. Stability, accurate low-volume dosing, preservative control, and device compatibility determine feasibility.

Are gelatin-free calcitriol capsules patentable?

Potentially, but patentability depends on the shell composition, technical performance, and prior art. A routine replacement of gelatin may not support strong claims without unexpected stability or manufacturing advantages.

What is the most important CMC issue for calcitriol capsules?

Content uniformity at the 0.25 mcg strength is usually the central CMC issue. Mixing, adsorption, fill accuracy, assay sensitivity, and sampling design require tight control.

Can a new calcitriol product receive orphan-drug exclusivity?

Orphan designation and exclusivity depend on the proposed indication and statutory criteria, not simply on using calcitriol in a new dosage form. A routine generic indication would not ordinarily create orphan exclusivity.

References

1. DailyMed. (n.d.). Rocaltrol: Calcitriol capsule prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product